Teva Pharmaceutical (TEVA) and Alvotech (ALVO) said Monday that Selarsdi has been approved by the US Food and Drug administration as interchangeable with the reference biologic Stelara.
Selarsdi, a human monoclonal antibody that selectively targets the p40 protein, is now interchangeable in all presentations of Stelara, which includes the treatment of psoriatic arthritis and plaque psoriasis, as well as Crohn's disease, and ulcerative colitis, the two companies said.
Teva shares were more than 7% higher in premarket trading, while Alvotech shares rose by nearly 2%.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。